Zafrens
- 15/12/2023
- Unknown
- $23,000,000
Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.
- Industry Biotechnology Research
- Website https://www.zafrens.com/
- LinkedIn https://www.linkedin.com/company/zafrens/about/
Related People
Kandaswamy (Swamy) VijayanFounder
Hi! I lead teams at the interface of biological, physical, computational and engineering sciences to build improbable products in biotech and pharma. My only real interest is to build a company that can last for generations. I use my interdisciplinary technical skills and ability to work with incredibly creative and grounded people to drive towards this goal.
[Technical CV: Invented core technologies for the highest accuracy short-read sequencing and highest throughput cell-based drug discovery available today.
Business CV: Closed $40M partnership with BMGF and led undisclosed large licensing evaluation with a leading diagnostics player while CEO of Omniome. Closed $20M partnership with Amgen and negotiated $35M contract with Abbvie while CEO of Plexium]